Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 7/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.53 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.50 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | THPO | P40225 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7980053 | 0.98 | TAAR1 (0.96) | TAAR1CHRM2CHRM1CHRM3ATM | |
| SCHEMBL10287496 | 0.89 | TAAR1 (0.79) | TAAR1CHRM2CHRM1CHRM3GPR84 | |
| SCHEMBL553063 | 0.81 | TAAR1 (0.68) | TAAR1GPR84CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL4399626 | 0.80 | TAAR1 (0.74) | TAAR1SMN1; SMN2 | |
| SCHEMBL11455326 | 0.80 | TAAR1 (0.67) | TAAR1GPR84CYP1A2MAPTTSHR | |
| SCHEMBL552961 | 0.79 | TAAR1 (0.66) | TAAR1GPR84CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL662360 | 0.79 | TAAR1 (0.66) | TAAR1CARM1PRMT6CYP1A2MAPT | |
| SCHEMBL29455232 | 0.79 | TAAR1 (0.66) | TAAR1CARM1PRMT6CYP1A2MAPT | |
| SCHEMBL5287659 | 0.79 | TAAR1 (0.64) | TAAR1CHRM2CHRM1CHRM3ATM | |
| Hydrochloric Acid SCHEMBL11526194 | 0.78 | TAAR1 (0.65) | TAAR1GPR84CYP1A2MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116829532-A | Substituted cyclohexane carboxamides, their preparation and their therapeutic use | 赛诺菲 | 2023-09-29 | — | — | CN | disclosed |
| EP-3743420-B1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA PLC (GB) | 2021-12-15 | — | — | EP | disclosed |
| EP-3068391-B1 | ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME (US) | 2018-05-23 | — | — | EP | disclosed |
| US-9783500-B2 | 2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition | NORTHWESTERN UNIVERSITY (US) | 2017-10-10 | — | — | US | disclosed |
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657006-B2 | Macrocyclic factor VIIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-28 | — | — | US | disclosed |
| EP-3008052-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-04-20 | — | — | EP | disclosed |
| WO-2014201073-A9 | MACROCYCLIC FACTOR VIIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-10-08 | — | — | WO | disclosed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997807-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008077625-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008077625-A1 | HETEROCYCLYL-SUBSTITUTED-EHYLAMINO-PHENYL DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-07-03 | — | — | WO | disclosed |
| EP-1935886-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-06-25 | — | — | EP | disclosed |
| EP-1935886-A1 | Heterocyclyl-substituted-ethylamino-phenyl derivatives, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-06-25 | — | — | EP | disclosed |
| US-20080004290-A1 | Anti-Cancer Agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-01-03 | — | — | US | disclosed |
| US-20080004290-A1 | Anti-Cancer Agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-01-03 | — | — | US | disclosed |
| WO-2005051901-A1 | ANTI-CANCER AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115159-A1 | MACROCYCLIC FACTOR VIIA INHIBITORS | F7, F12, F5 | TAAR1 4767/4885CHRM2 4332/4885CHRM1 4613/4885 |
| US-20080004290-A1 | Anti-Cancer Agents | TP53, TOP2A, MCL1 | TAAR1 4733/4885CHRM2 4854/4885CHRM1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.